[BioInvest News]FDA Supports Gene Therapy — At the Alliance for Regenerative Medicine’s Annual Board Meeting (May 22, Washington, DC), the FDA’S Scott Gottlieb gave a very positive statement on cell and gene therapy. Gottlieb says the agency is working to expedite development programs, starting with hemophilia. The agency will soon release the framework to explain how the FDA intends to address manufacturing issues and drug development. Link to Gottlieb’s gene therapy speech.
View the latest company updates from our recommended portfolio.
3 Biotech Best Bets From the ‘Stock Picker of the Year’
(May 24, 2018) At MoneyShow Las Vegas May 14-16, biotech sector expert John McCamant was given the show's "Stock Picker of the Year" award. Indeed, in 2017, the model portfolio of his The Medical Technology Stock Letter rose 65% while his trader's portfolio rose 98%. Here's a look at three of his current favorite stocks. […more]
Biotech Investors Should Consider The Four Horsemen
(April 6, 2018) One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John McCamant and frequent MoneyShow.com contributor. Medical Technology Stock Letter has had many such winners over the years, including Genentech and Pharmacyclics. We provided multiple entry points to invest in Pharmacyclics starting at $17 and in three-plus years the company was sold to AbbVie for $262 per share or $21 billion. Over the last year and a quarter, our subscribers have been enjoying incredible gains with the Four Horsemen: Esperion Therapeutics. Madrigal Pharmaceuticals, Nektar Therapeutics, Sangamo Therapeutics.[…more]
10 Favorite Healthcare Stocks for 2018
(January 19, 2018) Healthcare has always been a popular sector in our yearly January survey of the newsletter community’s favorite stocks. In MoneyShow’s 35th annual Top Stock Picks report, we see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches such as life sciences, vaccines, medical marijuana, opioid addiction and women’s health.[…more]
Biotech Poised for Significant Catalysts in 2018
(January 10, 2018) As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. 2017’s Outstanding Performance Was Led by the Four Horsemen In 2017, Medical Technology Stock Letter had four recommendations deliver outstanding[…more]
What Last Year’s Top Stock Pickers Are Buying In 2018
(January 5, 2018) At the start of each year for over three decades, the editorial team at MoneyShow.com surveys the nation’s leading newsletter advisors for their favorite stocks for the year ahead. We asked last year’s six top performers for an update on their 2017 picks and for their new favorite buys for 2018.[…more]